On Friday, February 23, the Colorado Prescription Drug Affordability Board (PDAB or Board) decided to initiate an “upper payment limit” (UPL) rulemaking process for the autoimmune disease drug Enbrel after deeming it “unaffordable for Colorado consumers” on February 16. The Denver Post described this decision as “a first-in-the-nation step that raises questions about whether a single state can reduce drug costs without unintended consequences.” CBSA submitted a comment letter in advance of the recent PDAB meeting and will continue to strongly advocate that UPLs are the wrong solution for patients in the coming months leading up to the PDAB’s decision on whether and how to set a specific UPL for the first time.
Enbrel UPL Vote
During the PDAB’s February 23 meeting, the Board voted to adopt the final Affordability Review Report for Enbrel…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
